| ACN | Acetonitrile |
| ADMET | Absorption, distribution, metabolism, excretion, and toxicity |
| AMES | The name of the test used in mutagenicity assessment |
| ATCC | American Type Culture Collection |
| BBB | Blood–brain barrier |
| BCRJ | Rio de Janeiro Cell Bank |
| Caco2 | Human colorectal adenocarcinoma cells |
| CC50 | 50% Cytotoxic Concentration |
| CL | Clearance capacity |
| CNS | Central nervous system |
| CPE | Cytopathic effect |
| CYP450 | Cytochrome P450 |
| DENV | Dengue Virus |
| DMEM | Dulbecco’s Modified Eagle Medium |
| DMSO | Dimethyl Sulfoxide |
| EC50 | 50% Effective Concentration |
| FBS | Fetal bovine serum |
| GC-MS | Gas chromatography-mass spectrometry |
| hERG | Human ether-go-go gene |
| HIV | Human Immunodeficiency Virus |
| ICTV | International Committee on Taxonomy of Virus |
| IFN-α-2a | Human recombinant interferon alfa-2a |
| LD50 | Lethal Dose for 50%. |
| LOAEL | Lowest observed adverse effect level |
| LogP | Logarithm of the partition coefficient |
| M.O.I | Multiplicity of infection |
| MRTD | Maximum recommended therapeutic dose |
| MTT | (3-(4,5-Dimetil-2-tiazolyl)-2,5-Difeniltetrazólio) |
| MVDA | Multivariate data analysis |
| NPX | Narciclasine-4-O-β-D-xylopyranoside |
| NS | Non-structural |
| OCT2 | Renal organic cation transporter 2 |
| RO5 | Lipinski’s Rule of Five |
| RT | Retention time |
| RVFV | Rift Valley Fever Virus |
| SARS | Severe acute respiratory syndrome |
| SISGEN | National System of Genetic Heritage Management |
| SMILES | Simplified Molecular Input Line Entry System |
| TMEM41B | Transmembrane Protein 41B |
| TRIM56 | Tripartite Motif Containing 56 |
| UHPLC | Ultra-high-performance liquid chromatograph |
| VDss | Volume of distribution at steady state |
| wt-YFV | Wild-type yellow fever virus |
| YF | Yellow fever |
| YFV | Yellow Fever Virus |
| ZIKV | Zika Virus |
| γ-PGA | polymer poly-γ-glutamic acid |